Maximizing clozapine utilization while minimizing blood dyscrasias: Evaluation of patient demographics and severity of events

International Clinical Psychopharmacology

Volumn 31, Issue 2, 2016, Pages 76-83

  Demler, Tammie Lee ^a,b   Morabito, Nicole E ^a   Meyer, Charlene E ^a   Opler, Lewis ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b Buffalo Psychiatric Center   (United States)

^c LONG ISLAND UNIVERSITY   (United States)

Author keywords

Blood dyscrasias; Clozapine; Clozaril; Neutrophil count; White blood count

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; AGE; AGED; ARTICLE; BLOOD DYSCRASIA; DEMOGRAPHY; DISEASE SEVERITY; ETHNICITY; FEMALE; FOOD AND DRUG ADMINISTRATION; GRANULOCYTOPENIA; GROUPS BY AGE; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PATIENT MONITORING; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; RACE; SCHIZOPHRENIA; SEX; SIDE EFFECT; ANCESTRY GROUP; BLOOD; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG MONITORING; ETHNOLOGY; MIDDLE AGED; NEUTROPENIA; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CONTINENTAL POPULATION GROUPS; DRUG MONITORING; FEMALE; HUMANS; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MIDDLE AGED; NEUTROPENIA; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84957851834     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000108     Document Type: Article

References (19)

1. Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993). Clozapine-induced agranulocytosis-incidence and risk factors in the United States. N Engl J Med 329:162-167.
2. Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D (1996). Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 169:483-488.
3. Clozapine REMS program (2015). https://www.clozapinerems.com [Accessed 27 October 2015].
4. Dettling M, Cascorbi I, Opgen-Rhein C, Schaub R (2007). Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J 7:325-332.
5. Fabrazzo M, Perris F, Salzano A, Luciano M, Catapano F (2012). P-1083-Transient and persistent blood dyscrasias induced by clozapine during the first 18 weeks of treatment. Eur Psychiatry 27:1.
6. Guenette MD, Powell V, Johnston K, Foussias G, Agid O, Hahn M, et al. (2013). Risk of neutropenia in a clozapine-treated elderly population. Schizophr Res 148:183-185.
7. Horácek J, Libiger C, Höschl K, Borzova I, Hendrychová J (2001). Clozapineinduced concordant agranulocytosis in monozygotic twins. Int J Psychiatry Clin Pract 5:71-73.
8. Ibáñez L, Vidal X, Ballarín E, Laporte J-R (2005). Population-based drug-induced agranulocytosis. Arch Intern Med 165:869-874.
9. Kerwin RW, Bolonna A (2005). Management of clozapine-resistant schizophrenia. Adv Psychiatr Treat 11:101-106.
10. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, et al. (1994). Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 151:1744-1752.
11. Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R (1999). Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 175:576-580.
12. Novartis (2013). Clozaril [package insert]. East Hanover, NJ: Novartis.
13. Opgen-Rhein C, Dettling M (2008). Clozapine-induced agranulocytosis and its genetic determinants. Pharmacogenomics 9:1101-1111.
14. Price K (1991). Ethnicity and clozapine-induced agranulocytosis. Clin Pharm 10:743-744.
15. Rajagopal S (2005). Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgrad Med J 81:545-546.
16. Ratanajamit C, Musakopas C, Vasiknanonte S, Reanmongkol W (2010). Incidence and risk for neutropenia/agranulocytosis among clozapine users: a retrospective cohort study. Int J Psychiatry Clin Pract 14:109-115.
17. Snowdon J, Halliday G (2011). A study of the use of clozapine in old age psychiatry. Int Clin Psychopharmacol 26:232-235.
18. The Clozapine Registry (2008). Teva clozapine monitoring guidelines. Sellersville, PA: Teva Pharmaceuticals USA.
19. Whiskey E, Olofinjana O, Taylor D (2011). The importance of the recognition of benign ethnic neutropenia in black patients during treatment with clozapine: case reports and database study. J Psychopharmacol 25:842-845.